ABSTRACT Background: Little is known about the combined effects of iron and n23 (omega-3) fatty acid (FA) supplementation on cognitive performance. The provision of either DHA/EPA or iron alone in rats with combined iron and n23 FA deficiency has been reported to exacerbate cognitive deficits associated with deficiency. Objective: We investigated the effects of iron and DHA/EPA supplementation, alone and in combination, in children with poor iron and n23 FA status. Design: In a 2-by-2 factorial trial, children with iron deficiency (ID) (n = 321; aged 6-11 y) were allocated to receive 1) iron (50 mg) plus DHA/EPA (420/80 mg), 2) iron plus placebo, 3) placebo plus a mixture of DHA and EPA (DHA/EPA), or 4) placebo plus placebo as oral supplements (4/wk) for 8.5 mo. Cognition was assessed at baseline and endpoint by using the Hopkins Verbal Learning Test (HVLT) and subscales of the Kaufman Assessment Battery for Children. Results: Both iron and DHA/EPA significantly increased weightfor-age z scores. Iron increased the number of words recalled at HVLT recall 2 (intervention effect: 0.90; 95% CI: 0.18, 1.62), and in anemic children, iron increased scores in the Atlantis Delayed test (1.51; 95% CI: 0.03, 2.99) and HVLT recall 2 (2.02; 95% CI: 0.55, 3.49). DHA/EPA showed no benefit in any of the cognitive tests but decreased Atlantis test scores (22.48; 95% CI: 23.99, 20.96) in children who were anemic at baseline and decreased Atlantis delayed scores (20.9; 95% CI: 21.45, 20.36) in girls with ID, whereas boys tended to perform better. Conclusions: In children with poor iron and n23 FA status, iron supplementation improved verbal and nonverbal learning and memory, particularly in children with anemia. In contrast, DHA/EPA supplementation had no benefits on cognition and impaired working memory in anemic children and long-term memory and retrieval in girls with ID. The trial was registered at clinicaltrials.gov as NCT01092377.
INTRODUCTION
Iron deficiency (ID) 5 is the most common micronutrient deficiency worldwide because increased requirements for growth are often not met by dietary sources (1) . Children with low fish and seafood intakes and a high use of vegetable oils that are rich in n26 fatty acids (FAs) are at risk of inadequate n23 FA intakes (2) . Both iron and n23 FAs are essential nutrients to ensure optimal growth and brain development (3) . Iron is required for neuronal growth and differentiation (4) and is a cofactor for enzymes involved in cell division as well as in the synthesis of neurotransmitters, myelin, and brain eicosanoids (5) (6) (7) (8) . In contrast, the long-chain PUFAs DHA (22:6n23) and EPA (20:5n23) play important roles in neuronal growth and differentiation as well as in myelination, monoaminergic neurotransmission, and eicosanoid synthesis (9) (10) (11) (12) . The deficiencies in iron and n23 FAs may interact directly via iron-dependent hepatic desaturases involved in the conversion of essential fatty acids into longchain PUFAs (13) .
Of the 6 randomized controlled trials (RCTs) of n23 FA supplementation in school-age children without diagnosed behavioral problems (14) (15) (16) (17) (18) (19) , 2 trials in South African children have shown a beneficial effect on verbal learning and memory (14, 15) . However, these trials differed markedly in length, cognitive outcome measures, form of n23 FAs provided, and doses used. Most RCTs of iron supplementation in school-age children included subjects with iron-deficiency anemia (IDA), and most trials showed a beneficial effect of iron on at least one cognitive or behavioral test (20, 21) . Whether iron supplementation can improve cognition in children suffering from ID without anemia is uncertain (22, 23) .
In a previous study, we showed that combined deficiencies of iron and n23 FAs in rats disrupted brain monoamine metabolism and produced greater deficits in reference memory than did ID or n23 FA deficiency alone (24) . In populations of low socioeconomic status that subsist on monotonous plant-based diets that are low in animal products and seafood, ID and n23 FA deficiency (relative to n26 FA) likely coexist and could have interactive effects on the cognitive development of children. We are aware of no previous RCT that investigated the effects of DHA and EPA and iron supplementation by using a 2-by-2 factorial design. The aim of this study was to determine whether the provision of iron and a mixture of DHA and EPA (DHA/ EPA), alone and in combination, to children with poor iron and n23 FA intake would affect their cognitive performance.
SUBJECTS AND METHODS

Study site
The study was conducted between November 2009 and November 2010 at 4 primary schools that serve low-income rural villages in the Province of KwaZulu-Natal in Eastern South Africa. This area is malaria free, and the schools are participating in the National School Nutrition Program, which provides children with a daily cooked school meal. South Africa implemented a mandatory flour-fortification program in 2003, whereby wheat flour and maize meal are fortified with electrolytic iron at 35 mg Fe/kg flour. Before the start of the study, the parents of all children in the first 5 grades at the schools were invited to attend a meeting at which the study purpose and procedures were explained. The subjects were asked to join the study, and written informed consent from the parents or guardians and verbal assent from the children were obtained. The ethical committees of the North-West University and Swiss Federal Institute of Technology Zürich approved the study protocol.
Subjects
In total, 926 children participated in the baseline screening. Inclusion criteria for the intervention were as follows: 1) 6-11 y of age; 2) hemoglobin concentration .8 g/dL; 3) ID, which was defined as either a serum ferritin (SF) concentration ,20 mg/L, zinc protoporphyrin (ZnPP) concentration .70 mmol/mol heme in washed erythrocytes, or serum transferrin receptor (TfR) concentration .8.3 mg/L; 4) apparently healthy, with no chronic illness; and 5) no consumption of iron or n23 FA-containing supplements. Two children who had hemoglobin concentrations ,8 g/dL were referred for medical treatment. In the screening, 349 children met the inclusion criteria and were asked to join the intervention. Results from a previous n23 FA supplementation study in primary school children showed that supplemented subjects scored 3 words more over time in the Hopkins Verbal Learning Test (HVLT) than control subjects did (15) . On the basis of these results, the sample size was calculated to detect a difference in the means of 2 words by using a common SD of 5.0, an a = 0.05, and a power of 80%. Thus, a minimum number of 78 children per group were required. With consideration of a 10% dropout rate, we planned to enroll 86 children per group.
Random assignment and blinding
To maintain anonymity, all subjects who participated in the baseline screening received a personal code, which was used throughout the study. Subjects who met the inclusion criteria were stratified first by school and by grade. Random assignment was performed by using a computer-generated list, which was blocked by school, and enrolled subjects were assigned treatment codes and respective group colors, which were used on supplement containers and forms throughout the trial. Participants, investigators, staff, and the sponsors were blinded to treatment assignment. Group codes were held by a member of an independent safety monitoring board until data analyses were completed.
Study design
The study used a randomized, placebo-controlled, doubleblind 2-by-2 factorial design. Children were randomly allocated to receive 1) iron plus DHA/EPA, 2) placebo plus DHA/EPA, 3) iron plus placebo, or 4) placebo plus placebo as oral supplements ( Figure 1) . The intervention began immediately after baseline cognitive screening at the beginning of the school year and continued throughout the whole school year (8.5 mo). All participating children were dewormed at baseline and after 4 mo with an oral dose of 400 mg mebendazole [Worm-Stop; Be-Tabs Pharmaceuticals (Pyt) Ltd].
Intervention
Iron-supplemented groups received one oral tablet of 50 mg iron as iron sulfate (Lomapharm; Paul Lohmann GmbH) on 4 d/ wk during school days. The respective non-iron-supplemented (placebo) groups received the same regimen of placebo tablets (Lomapharm; Paul Lohmann GmbH) that were identical in appearance to the iron tablets. The DHA/EPA-supplemented groups received 2 oral gelatin-coated fish-oil capsules that contained a total of 420 mg DHA and 80 mg EPA (Burgerstein AG) on 4 d/wk during school days. The respective non-DHA/EPAsupplemented (placebo) groups received the same regimen of placebo capsules that contained medium-chain triglycerides (RP Scherer GmbH). Placebo capsules were identical in appearance and total fat content to DHA/EPA capsules.
The iron or placebo tablets were administered in the morning directly after the children had arrived at school (before 0800). Tablets were swallowed with a 200-mL fruit-flavored beverage that contained w10 mg vitamin C/serving. DHA/EPA or placebo capsules were administered during the midmorning break before children received the school meal (between 1030 and 1100). Thus, there was a time-period of w2.5 h between the iron and DHA/EPA supplementation to minimize potential side effects of a concomitant supplementation. Trained field workers (one field worker per group and school) directly supervised the tablet consumption and recorded compliance and illness symptoms while absent or present.
The study was supervised by an independent safety monitoring board. Two board members performed 2 field visits during the study and data collection. All children who remained with ID at the end of the study received additional iron supplementation.
Supplementation took place from mid-February to November 2010 and was interrupted by holidays for 2 wk in March and April, for 5 wk in June and July, and for 1 wk in September. Supplementation was further interrupted for 4.5 wk by a national strike of teachers in August and September. To catch up on the unexpected loss of intervention days, supplementation was increased from 4 to 5 d/wk for 8 wk, which compensated for 2 wk of supplementation. Thus in total, supplements were provided for 105 d over a period of 8.5 mo.
Biochemical indicators
Venous blood samples (10 mL) were drawn into EDTA-coated and into trace-element free evacuated tubes (Becton Dickinson) at baseline and endpoint. Hemoglobin concentrations were measured on site on an aliquot of whole blood by using the direct cyanmethemoglobin method [Ames Mini-Pak hemoglobin test pack and Ames Minilab, Bio Rad Laboratories (PTY) Ltd] by using Drabkin's solution and a standard miniphotometer. Remaining blood samples aliquots were prepared at 500 3 g for 15 min at room temperature, and plasma and serum aliquots were prepared and stored at 220 8 C for the duration of the fieldwork (4 d). Red blood cells (RBCs) were washed twice with 0.15 mol NaCl/L and centrifuged at 500 3 g for 10 min to remove the buffy coat.
ZnPP was measured on washed RBCs by using a hematofluorometer (Aviv Biomedical) and 3-level control material provided by the manufacturer on the same day of blood sampling. After completion of the fieldwork, samples were transported on dry ice and stored at 280 8 C until analysis. SF and C-reactive protein (CRP) were measured by using an automated chemiluminescent immunoassay system (IMMULITE; DPC Bühlmann GmbH). Serum TfR was measured by using an enzyme immunoassay (Ramco Laboratories Inc). Body iron was calculated from the ratio of TfR:SF according to the equation of Cook et al (25) . ID was defined as either a ZnPP concentration .70 mmol/mol heme (26), TfR concentration .8.3 mg/L (testkit reference value), or SF concentration ,15 mg/L (27) . For the reporting of prevalence and statistical analyses, an SF concentration ,15 mg/L was used to define ID; for inclusion into the study, an SF concentration ,20 mg/L was used. Anemia was defined as a hemoglobin concentration ,11.5 g/dL (28) . Inflammation was defined as a CRP concentration .5 mg/L. SF values of subjects with CRP concentrations .5 mg/L were excluded from the analysis because of the confounding effects of inflammation on SF.
FA analyses in RBCs were performed within 3 mo after collection. Phospholipids were extracted from RBC membranes with chloroform:methanol (2:1 vol:vol; containing 0.01% butylated hydroxytoluene) by using a modification of the method of Folch et al (29) . Lipid extracts were concentrated, and the neutral lipids were separated from the phospholipids by using thin-layer chromatography (silica gel 60 plates, 10 3 20 cm; Merck) and eluted with diethyl ether:petroleum ether:acetic acid (30:90:1 vol:vol:vol). The lipid band that contained phospholipids was 
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removed from the thin-layer chromatography plate and transmethylated with methanol:sulphuric acid (95:5 vol:vol) at 70 8 C for 2 h to yield fatty acid methyl esters (FAMEs). The resulting FAMEs were extracted with water and hexane. The organic layer was evaporated, redissolved in hexane, and analyzed by using quadrupole gas chromatography-electron impact-mass spectrometry on an Agilent Technologies 7890A Gas Chromatograph system equipped with an Agilent Technologies 5975C VL mass selective detector (Agilent Technologies). The gas chromatography separation of FAMEs was carried out on an BPX 70 capillary column (60 m 3 0.25 mm 3 0.25 mm; SGE Analytic Sciences) by using helium as the carrier gas at a flow rate of 1.3 mL/min. The gas chromatography injector was held at a temperature of 280 8 C, and the mass spectrometry source was maintained at temperatures of 230 8 C. The injection volume of the sample solution was 1 mL by using a split ratio of 1:1. The oven temperature was programmed from 130 8 C to 240 8 C, rose from 130 8 C to 200 8 C at 2 8 C/min, was held at 200 8 C for 4 min, and then rose at 5 8 C/min to 220 8 C. After the temperature was held isothermal at 220 8 C for 5 min, it was increased by 10 8 C/min to 240 8 C, where it was retained for 5 min. The total analysis time was 53 min. Mass spectrometry with 70 eV electron ionization was carried out in full-scan acquisition mode, and all mass spectra were acquired over the m/z range of 50-550. Quantification of FAME was done by using the selected-ion extraction method on the basis of the response of 2 diagnostic ions. FAME peaks were identified and calibrated against 2 standard reference mixtures of 26 and 8 FAMEs, respectively (Nu-Check-Prep) and 3 single FAME standards (Larodan Fine Chemicals AB). Data analysis was performed by using ChemStation mass spectrometry data software (Agilent G1701EA version E.02.00.493). Relative percentages of fatty acids were calculated by taking the concentration of a given fatty acid derivative as a percentage of the total concentration of all fatty acids identified in the sample.
Cognitive assessment
A battery of cognitive tests was selected, designed, or adapted for this age and culture group. These were 4 selected subtests of the Kaufman Assessment Battery for children aged 3-18 y, second edition (KABC-II) (30) and the HVLT (31). The Atlantis (working memory) and Atlantis Delayed (long-term memory and retrieval) tests were chosen from the learning scale of the KABC-II. The Hand Movement test (short-term memory) was chosen from the sequential processing scale, and the Triangles test (visuospatial cognition) was chosen from the simultaneous processing scale. The procedures of these tests and of the HVLT were described previously (14, 17, 32) .
Cognitive performance was assessed at baseline and endpoint. A team of 7 local cognitive assessors were carefully trained by an experienced psychologist. Training was repeated in the week before cognitive assessment at baseline and endpoint. All testers were blinded with regard to group allocation. Because these rural schools only have intermittent electricity, paper-and-pencil procedures were used, and timing was done by using batterydriven electronic stop-watches. All tests were conducted in the local language (Zulu) and have been previously validated with local children of a similar age. The testing was done in a semiprivate setting and took a child w30-45 min to complete. Scores from the KABC-II subtests were standardized (age-adjusted) by using the KABC-II Assist software package (version 2; Pearson Education Inc). No normalized scores for the HVLT test performance are available for a population of healthy normal children. Thus, all statistical analyses were adjusted for age.
Anthropometric measures
Body weight was measured without shoes and outerwear and in light clothing to the nearest 0.01 kg on a load-cell-operated digital scale (Masskot, UC-300 Precision Health Scale; A&D Co), which was calibrated by using fixed weights. Height was measured (without shoes) to the nearest 0.1 cm by using a rigid stadiometer, which was calibrated by using a steel tape. The ageand sex-specific height-for-age z score (HAZ), weight-for-age z score (WAZ), and BMI-for-age z score (BAZ) were calculated by using the 2007 WHO growth standards for children aged 5-19 y with software WHO Anthro Plus for personal computers (version 1.0.3, 2010). Stunting was defined as an HAZ less than 22, mild stunting was defined as an HAZ less than 21 and greater than 22. Children with a WAZ less than 22 were classified as underweight, children with a BAZ .1 and ,2 were classified as overweight, and children with a BAZ $2 were classified as obese. WAZ scores were available only for children ,11 y of age.
Statistical analyses
Statistical analyses were performed by using IBM SPSS Statistics (version 19; IBM Co). All data were checked for normal distribution and the presence of outliers (63 SD from the mean). Skewed variables were transformed before data analyses. Data analyses were performed by treating dropouts (Figure 1 ) and missing data (biochemical, anthropometric, and cognitive data; ,5%) by using multiple imputations under the assumption that values were missing at random. Five imputations were produced for all outcome variables by using an iterative Markov chain Monte Carlo method and a linear regression model that included the treatment group (iron; DHA/EPA), a treatment-interaction term (iron 3 DHA/EPA), age, sex, school, and compliance as independent predictors. Estimated intervention effects of iron (iron compared with placebo) and of DHA/EPA (DHA/EPA compared with placebo) and their interaction were analyzed by using 2-factor ANCOVA on the endpoint measurement by using baseline values, sex, age, school, and compliance (total doses of iron and DHA/EPA) as individual level covariates. Cognitive data were also adjusted for the respective cognitive assessor. Baseline differences in cognitive performance scores between children with IDA and children with nonanemic ID and between girls and boys were analyzed by using independent t tests. To investigate potential interactions of sex or anemia with iron and DHA/EPA treatment on endpoint cognitive test scores, a 3-factor ANCOVA that included sex (boys compared with girls) or anemia (IDA compared with nonanemic ID) and iron (iron compared with placebo) and DHA/EPA (DHA/EPA compared with placebo) as fixed factors was performed on endpoint cognitive test scores with baseline values, sex, age, school, cognitive assessor, and compliance (total doses of iron and DHA/EPA) as individual level covariates. When the sex 3 treatment or anemia 3 treatment interaction was significant, appropriate subgroup analyses were performed. P , 0.05 was considered significant.
RESULTS
Subjects
In the 926 children who were screened for the study, the baseline prevalence of ID was 10.5% on the basis of SF and 4.8% and 40.5% on the basis of TfR and ZnPP, respectively. The prevalence of anemia was 18.6%. From the 349 children who met the inclusion criteria, a final number of 321 children were randomly allocated to the 4 treatment groups after 28 children were no longer available because of different reasons. Only one serious adverse event (pulmonary tuberculosis) was reported during the trial, which was not related to treatment. A total of 25 children (7.8%) did not complete the study because they either left school (n = 4), did not like taking the supplements (n = 9), complained about side effects (headache, abdominal discomfort, or nausea; n = 4), withdrew for unknown reasons (n = 6), or had been diagnosed with chronic infectious disease (pulmonary tuberculosis; n = 1). The dropout rates were 12.3% (n = 10), 7.4% (n = 6), 5.1% (n = 4), and 6.3% (n = 5) in the iron plus placebo, placebo plus DHA/EPA, iron plus DHA/EPA, and placebo plus placebo groups, respectively. There was no significant difference in dropout rates between treatment groups. Two children refused the final blood draw, and thus, a total of 294 children completed the follow-up (Figure 1 ). During the cognitive testing at endpoint, 6 more children were not available for assessment.
Baseline characteristics of the children in each group are shown in Table 1 . There were no relevant differences in any baseline characteristics between treatment groups.
Intervention
Compliance was high; the mean adherence to treatment (observed capsules and tablets swallowed during the 105-d trial) was 95.4% (,80% for only 8 children) and did not differ between treatment groups. The mean total iron intake during the 105-d trial was 4.8 g in the groups that received iron tablets, and the mean total DHA and EPA intake was 41.2 g and 7.8 g, respectively, in the groups that received DHA/EPA capsules.
Biochemical indicators
Concentrations of iron-status indicators and the relative composition of n23 and n26 long-chain PUFAs of erythrocyte membranes at baseline and after the 8.5-mo intervention by treatment groups are shown in Table 2 . In the 2-factor ANCOVA adjusted for respective baseline values, sex, age, school, and compliance, there were iron-treatment effects on all iron indexes for improved iron status (all P , 0.001). Although there were small increases (within the normal reference range) in median TfR from baseline to endpoint in all groups, there was a significant effect of iron treatment for lower TfR concentrations (P , 0.001) at endpoint. Moreover, the prevalence of ID on the basis of TfR decreased nonsignificantly from 16.0% in the iron plus placebo and 15.2% in the iron plus DHA/EPA groups at baseline to 9.9% and 7.6%, respectively, at endpoint, whereas the ID 1 BAZ, BMI-for-age z score; DHA/EPA, mixture of docosahexaenoic acid and eicosapentaenoic acid; HAZ, height-for-age z score; WAZ, weight-for-age z score; SF, serum ferritin; SZn, serum zinc; TfR, transferrin receptor; ZnPP, zinc protoporphyrin.
2 Mean 6 SD (all such values).
3 SF values of all subjects with a C-reactive protein concentration .5 mg/L were excluded. 4 Total body iron was calculated on the basis of Cook et al (25) . Fatty acids were measured in the total phospholipid fraction of erythrocyte membranes. Intervention effects were estimated by using ANCOVA adjusted for respective baseline values, sex, age, school, and compliance. ARA, arachidonic acid; CRP, C-reactive protein; DHA/EPA, mixture of docosahexaenoic acid and eicosapentaenoic acid. Median; minimum to maximum in parentheses (all such values). Data were log transformed to perform ANCOVA.
6
Total body iron was calculated on the basis of Cook et al (25) .
7
Data were square root transformed to perform ANCOVA.
8
Data were squared to perform ANCOVA.
9
Data were log transformed to perform ANCOVA.
prevalence on the basis of TfR increased significantly from 6.2% in the placebo plus DHA/EPA group and 8.8% in the placebo plus placebo group to 21.0% and 26.3%, respectively. Anemia prevalence decreased from 20.6% to 1.9% in children who received iron (P , 0.001) and decreased from 21.1% to 5.0% in children who received the placebo (P , 0.001). There was an iron 3 DHA/EPA interaction (P , 0.05) on ZnPP concentrations; iron treatment in combination with DHA/EPA decreased ZnPP concentrations to a greater extent than did iron treatment alone. DHA/EPA supplementation significantly increased the relative composition of EPA and DHA in the total phospholipid (TPL) fraction of erythrocyte membranes and decreased arachidonic acid and the n26:n23 FA ratio in membranes (P , 0.05).
Growth
Anthropometric indexes at baseline and after the 8.5-mo intervention by treatment groups are shown in Table 3 . There was a significant effect of DHA/EPA for higher body weight at endpoint. Furthermore, there were significant effects of DHA/ EPA as well as of iron treatment for higher WAZ at endpoint.
Cognitive performance
All groups showed a significant improvement in the Kaufman Assessment Battery for Children (KABC) tests that assessed learning abilities and simultaneous processing from baseline to endpoint, whereas scores for sequential processing decreased significantly, except in the placebo plus DHA/EPA group (Table  4) . However, there was no significant intervention effect and no iron 3 DHA/EPA interaction on any KABC test scores.
Endpoint scores for the HVLT were generally lower than those at baseline, which could possibly be explained by the different sets of words that were used at the 2 time points. There was a significant effect of iron for higher endpoint scores in the HVLT recall 2; 0.90 more words were recalled (out of 12) at the second trial by children who were treated with iron compared with placebo groups. However, there were no other significant intervention effects and no interactions on any other HVLT scores.
Subgroup analyses
Baseline hemoglobin categories (,11.5 compared with $11.5 g/dL)
We showed significant differences in baseline HLVT recall 3 and HVLT discrimination index scores between children with IDA [n = 66 (38 boys and 28 girls)] and children with nonanemic ID [n = 253 (125 boys and 128 girls) at baseline]. Furthermore, there was a significant anemia (anemic compared with nonanemic) 3 DHA/EPA interaction on Atlantis scores and an anemia 3 iron interaction on Atlantis Delayed scores. Therefore, we assessed the effects of iron and DHA/EPA supplementation on each of these 2 sub-groups (anemic compared with nonanemic) separately (data not shown). HVLT recall 2 scores (2.02; 96% CI: 0.55, 3.49) were significantly higher, and HVLT total recall scores (2.97; 95% CI: 20.25, 6.19; P = 0.07) tended to be higher in anemic subjects treated with iron. Subgroup analyses further revealed significant effects of DHA/EPA for lower Atlantis test scores (22.48; 95% CI: 23.99, 20.96) (Figure 2A ) and of iron for higher Atlantis Delayed scores (1.51; 95% CI: 0.03, 2.99) ( Figure 2B ) at endpoint in anemic children. No significant treatment effects on KABC and HVLT performance were shown in the children with nonanemic ID.
Boys compared with girls
There was no significant difference in cognitive test performance at baseline between boys and girls. There was also no difference between the anemia prevalence in boys (23%) and girls (18%). However, there was a significant sex 3 DHA/EPA interaction on Atlantis Delayed scores and a sex 3 iron interaction on HVLT recall 2 scores at endpoint. In girls, there was a significant negative effect of DHA/EPA supplementation on Atlantis Delayed test performance (20.90; 95% CI: 21.45, 20.36), whereas boys supplemented with DHA/EPA tended to perform better (0.78; 95% CI: 20.19, 1.75; P = 0.09) (see Figure 1A under "Supplemental data" in the online issue). Conversely, the effect of iron for higher HVLT recall 2 scores was significant in girls (1.18; 95% CI: 0.16, 2.20) (see Figure 1B under "Supplemental data" in the online issue) and only tended to be significant in boys (0.497; 95% CI: 20.57, 1.56; P = 0.059). In addition to the effect of iron in girls, there was also a significant iron 3 DHA/EPA interaction; girls who received iron or DHA/ EPA alone recalled more words at HVLT recall 2 than girls did who received the combined treatment or placebo plus placebo.
DISCUSSION
To our knowledge, this was the first RCT to investigate the effects of DHA/EPA and iron supplementation, alone and in combination, on cognition in school-age children. Over the study period of 38 wk, the iron intervention provided an additional w18 mg Fe/d. This fairly high iron dose (33), the good bioavailability of iron from ferrous sulfate in combination with vitamin C, and the long study period led to a robust increase in body iron stores. The median SF concentration increased w3-fold, and there were significant iron-intervention effects for increased body iron and hemoglobin; the prevalence of anemia significantly decreased from 20.6% at baseline to 1.9% at endpoint. One of the major limitations of the study was that the intervention mainly increased iron stores because few children had clear signs of iron-deficient erythropoiesis or IDA at baseline. In the 2005 National Food Consumption Survey of South Africa, the prevalence of anemia, ID (defined as an SF concentration ,12 mg/L), and IDA was 21.7%, 13.3%, and 5.9%, respectively, in 1-9 y old children living in KwaZulu-Natal (the province in which the study was located) (34) . South Africa implemented a fortification program in 2003 that made it mandatory to fortify wheat flour and maize meal, which are the major staple foods in our study population (35) . The fortification program may help explain why, in our screening population (n = 926), the prevalence of ID on the basis of SF and TfR was only w5-10%. However, nearly 1 in 5 children was anemic. The high prevalence of mild anemia may have been due to hemoglobinopathies (such as sickle cell disease or thalassemia) or other micronutrient deficiencies (eg, folic acid and vitamin B-12).
The children included in the study had poor n23 FA status at baseline, as reflected in the low relative composition of DHA in TPLs of erythrocyte membranes (a good indicator of tissue FA
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TABLE 3
Effects of intervention with iron and DHA/EPA, alone and in combination, on indicators of growth over 8.5 mo Median; minimum to maximum in parentheses (all such values). Data were log transformed to perform ANCOVA.
5
Available only for subjects ,11 y of age (n = 267).
TABLE 4
Effects of intervention with iron and DHA/EPA, alone and in combination, on cognitive performance over 8.5 mo composition) (36) and in a dietary assessment in the study population (data not shown) that showed a very high n26:n23 intake ratio of w60:1. Over the study period of 38 wk, the DHA/ EPA intervention provided an additional w155 mg DHA and 29 mg EPA/d. This addition sharply increased the median relative composition of EPA and DHA in TPLs of erythrocyte membranes by 127% and by 95%, respectively. Thus, n23 FA supplements clearly improved the n23 FA status. We showed no significant intervention effects of DHA/EPA on any of the cognitive tests. Several previous studies of n23 FA fortification or supplementation that also did not find a significant effect on cognition used lower EPA/DHA doses, has a shorter study period, or provided the precursor a-linolenic acid (16) (17) (18) (19) . In contrast, 2 previous RCTs conducted in South African school children, one of which provided n23 PUFA supplements (which supplied w250 mg n23 FAs 5 times/wk) over a period of 9 mo and the other of which provided a bread spread that contained n23 PUFA-rich fish flour (which supplied w892 mg DHA/wk) for 6 mo, reported an improvement of verbal learning and memory by using the HVLT (14, 15) . However, in the latter study, other ingredients in the spread (eg, amino acids) may have contributed to the benefits for cognition.
In the current study, we showed a significant but small effect of iron supplementation only for recall 2 in the HVLT; the children had a better ability to recall the 12 words from the word list during the second trial (plus w1 word). This finding was consistent with 2 RCTs in adolescent girls with ID without anemia that showed significant iron-treatment effects on HVLT recall scores (37, 38) . Similarly, we showed that the effect of iron treatment was only significant in girls.
Subgroup analyses revealed significant differences in baseline cognitive scores between children with IDA and children with nonanemic ID. Observational studies in children and adolescents have generally shown an association between IDA and poor cognitive performance, whereas the adverse effects of ID without anemia remain uncertain (20, 21) . In our study, in children with IDA at baseline, iron supplementation significantly increased the number of words recalled at HVLT recall 2 (plus 2 words out of 12) and improved Atlantis Delayed scores (test of long-term memory and retrieval), whereas no effects were shown in their counterparts with nonanemic ID. Despite the small sample size in the anemic subgroup, these results suggest that iron treatment may be beneficial only in children suffering from IDA. A recently published review concluded that school-age children with IDA are most likely to gain a cognitive benefit from iron supplementation (23) .
We showed a significant and large negative effect of DHA/EPA on Atlantis test scores (test of working memory) in children who were anemic at baseline. In addition, there was a negative effect of DHA/EPA supplementation on Atlantis Delayed scores in girls with ID, whereas boys with ID tended to perform better with DHA/EPA supplementation. The anemia prevalence was equal between boys and girls, which did not suggest that the negative effect in girls with ID was driven by anemia. Sex-specific differences in the response to treatment have been observed in previous n23 FA trials; however, the direction and extent of the effects were not consistent across different age groups and outcome measures (39, 40) . More studies are needed that are powered enough to perform subgroup analyses by sex. The observed negative effects of DHA/EPA supplementation in subjects with ID and IDA were consistent with a recent study that showed that rats deficient in both iron and n23 FAs performed worse in test of spatial working memory and reference memory in the Morris water maze after repletion with DHA/ EPA alone than did rats that remained doubly deficient (41) . In that study, working-memory deficits were not reversible, whereas reference (long-term) memory improved when rats were repleted with a combination of DHA/EPA and iron. The mechanisms that underlie the adverse effects of providing either DHA/EPA or iron alone to rats with combined deficiency are uncertain but may involve the disruption of neurotransmitter balance in a brain that has adapted to chronic deficiency. Alternatively, the exposure of cells to moderate amounts of iron may be necessary to adapt cells to oxidative stress (42, 43) . Because oxidative stress can trigger inflammation that may cause cognitive impairment (44) , it is possible that the provision of either iron or DHA/EPA alone produces greater inflammation than does the combined provision of iron and DHA/EPA. These mechanisms may also potentially explain the negative effects of DHA/EPA supplementation when given alone to children with IDA in the current study. by supplementation group for total study children and children who were anemic and nonanemic at baseline separately. Intervention effects were estimated by using 2-factor ANCOVA on the endpoint measurement with adjustment for the respective baseline value, sex, age, school, compliance (total doses of iron and DHA/ EPA), and respective assessor (P , 0.05). DHA/EPA, mixture of docosahexaenoic acid and eicosapentaenoic acid.
The relatively wide age range from 6 to 11 y and a potential bias of cognitive assessors on the test performance of subjects may have contributed to the lack of effect of DHA/EPA supplementation. Also, these children from a low socioeconomic background were likely to have been deficient in n23 FAs during earlier periods in development (2). Emerging evidence from animal studies has suggested that cognitive deficits induced by an n23 FA deficiency during early development may not be reversible (45) (46) (47) . Thus, it is possible that supplementation during school age is too late to achieve beneficial effects on cognitive performance. There is sound evidence from animal studies that deficiencies in iron and n23 FAs alter brain monoamine systems, including dopamine and serotonin, which are involved in mood and behavior, and these alterations are at least partially reversible with supplementation (45, 48, 49) . Thus, the assessment of additional behavioral or emotional components may be useful in future studies in this age group.
In conclusion, our data suggest that 1) iron supplementation has beneficial effects on cognition in children with IDA and poor n23 FA status, 2) DHA/EPA supplementation has no benefit on cognition in children with poor n23 FA status and ID, and 3) DHA/EPA supplementation has a strong negative effect on working memory in children with IDA and on long-term memory and retrieval in girls with ID, whereas boys with ID tend to benefit from DHA/EPA supplementation. The negative effect of DHA/EPA supplementation may have confounded previous studies done in areas with a high prevalence of ID and IDA that focused only on the effects of n23 FA supplementation. Additional research is needed to confirm this result and to elucidate the underlying mechanisms.
